Terms: = Bone cancer AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Treatment
5 results:
1. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA
Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607
[TBL] [Abstract] [Full Text] [Related]
2. Extrascleral extension of choroidal melanoma after iodine-125 brachytherapy treatment: a case series.
Mustak H; Lo C; Cohen LM; Tran A; Almanzor R; McCannel TA; Goldberg RA; Rootman DB
Eye (Lond); 2023 Feb; 37(2):249-255. PubMed ID: 34987200
[TBL] [Abstract] [Full Text] [Related]
3. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract] [Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract] [Full Text] [Related]
5. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract] [Full Text] [Related]
